- Anavex Life Sciences' (NASDAQ:AVXL) oral drug candidate blarcamesine (ANAVEX2-73) slowed cognitive decline in a phase 2b/3 study.
- Shares are up ~3% in Thursday premarket trading.
- The trial was conducted in ~500 participants with early symptoms of Alzheimer's, including mild cognitive impairment and mild dementia. Patients were randomized to receive blarcamesine or placebo once daily over 48 weeks.
- Results showed clinically significant differences in ADAS-Cog13 and CDR-SB, two Alzheimer's disease assessment scales, between the treatment and placebo arms.
- In addition, biomarkers of amyloid beta, a plaque found in the brains of those with Alzheimer's, indicated anti-amyloid effects of blarcamesine. Also, brain MRIs showed a significant reduction in brain volume loss in the blarcamesine-treated group.
- Anavex (AVXL) said that blarcamesine "restores cellular homeostasis by targeting sigma-1 and muscarinic receptors."
- Forums
- ASX - By Stock
- CGS
- More good news
More good news
Featured News
CC9
Chariot Corporation (ASX:CC9) refines Black Mountain strategy, launching Pilot Mine to seize U.S. lithium opportunity
NEWS
Antler Copper Project hits major permitting milestone – air quality permit advances to final review
Add CGS (ASX) to my watchlist
(20min delay)
|
|||||
Last
90.5¢ |
Change
-0.060(6.22%) |
Mkt cap ! $156.1M |
Open | High | Low | Value | Volume |
96.0¢ | 97.5¢ | 90.5¢ | $502.8K | 529.3K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 20000 | 90.0¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
92.5¢ | 1101 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 20000 | 0.900 |
4 | 48873 | 0.890 |
1 | 1000 | 0.860 |
1 | 1055 | 0.850 |
1 | 411 | 0.790 |
Price($) | Vol. | No. |
---|---|---|
0.925 | 1101 | 1 |
0.935 | 4374 | 1 |
0.960 | 1000 | 1 |
0.970 | 416 | 1 |
1.000 | 8516 | 1 |
Last trade - 15.59pm 04/10/2024 (20 minute delay) ? |
Featured News
CGS (ASX) Chart |